Catalyst Event
Duality Biotherapeutics Inc (9606) · Other
From Akros SCHK HK-U.S. Tech 100 Index (ASHUSTC)
5/12/2026, 12:00:00 AM
Announced the exercise of its option to co-develop and share costs and profits/losses for its core drug candidate DB-1311/BNT324 in the U.S. market with partner BioNTech.
Korean Translation
파트너인 바이오엔테크(BioNTech)와 핵심 신약 후보물질 DB-1311/BNT324에 대한 미국 시장 공동 개발 및 비용/손익 분담 옵션을 행사했다고 발표함.
Related Recent Events
3SBio Inc (1530) · Earnings Release
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
8/26/2026, 12:00:00 AM
Microsoft Corp (MSFT) · Earnings Release
Microsoft is scheduled to report its Q4 and full-year fiscal 2026 earnings results on 2026-07-28, with analysts forecasting EPS around $4.24-$4.33. High importance is estimated due to typical 10% price volatility following earnings scheduled.
7/28/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Other
AMD's 'Advancing AI 2026' event to detail future AI product roadmaps on July 23, 2026 is expected to have a 5% price impact scheduled.
7/23/2026, 12:00:00 AM
Amphenol Corp (APH) · Earnings Release
Next quarterly earnings release for Q2 2026 is a routine administrative event with low expected impact, scheduled.
7/22/2026, 12:00:00 AM
Thermo Fisher Scientific Inc (TMO) · Earnings Release
Q2 2026 earnings release scheduled for 2026-07-22; low importance estimated as earnings typically cause moderate volatility, expected.
7/22/2026, 12:00:00 AM
3SBio Inc (1530) · Other
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
7/21/2026, 12:00:00 AM